ADAPTIN BIO
Live / Allowed — Notice of allowance issued (as of 21 Oct 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 12 Sept 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98746952
- Mark type
- Stylized text
- Filed
- 12 Sept 2024
- Published for opposition
- 26 Aug 2025
- Attorney of record
- Devon E. White
Goods and services
- Class 001 — Chemicals: Biological preparations for use in the manufacture of pharmaceuticals
- Class 005 — Pharmaceuticals: Biological preparations for treatment of cancers, central nervous system diseases and autoimmune disorders; Medical preparations and pharmaceuticals for treatment of cancers, central nervous system diseases and autoimmune disorders; Drug delivery agents in the form of an injectable liquid suspension that facilitate delivery of pharmaceutical preparations; Drug delivery platform, namely, drug delivery agents in the nature of cellular products being an injectable liquid suspension that facilitates delivery of pharmaceuticals; Pharmaceutical preparations for the treatment of cancers, central nervous system diseases and autoimmune disorders using compounds comprising of manipulated immune cells
- Class 042 — Scientific and technological services: Research in the field of biotechnology and pharmaceutical development; Research and development of platform technologies for delivery of therapies; Research and development of platform technologies for delivery of antibody therapies, cell therapies and pharmaceuticals; Research and development regarding the use of immune system cells to discover, research and develop novel platform technologies for delivery of therapies and pharmaceuticals; Pharmaceutical research and development for the treatment of cancers, neurological diseases, and neurological disorders and autoimmune disorders; Scientific research in the field of drug delivery platforms, cell therapies and pharmaceuticals; Pharmaceutical research services; Research and development of pharmaceutical preparations for treatment of cancers, neurological diseases and disorders and autoimmune diseases; Research and development in the fields of pharmaceuticals and biotechnology; Research and development regarding the delivery of drug therapies across the blood-brain barrier and other physiological barriers; Research and development regarding the delivery of drug and cell therapies to targeted body tissue; Research and development regarding the identification and targeting of specific cells for drug therapies
Owner
- Adaptin Bio, Inc., Charlotte, NC, US
- Adaptin Bio, Inc., Charlotte, NC, US
Prosecution history
- 21 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Aug 2025 — PUBLISHED FOR OPPOSITION
- 20 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 24 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Jul 2025 — EXAMINER'S AMENDMENT ENTERED
- 23 Jul 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 23 Jul 2025 — EXAMINERS AMENDMENT E-MAILED
- 23 Jul 2025 — EXAMINERS AMENDMENT -WRITTEN
- 18 Jul 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 18 Jul 2025 — FINAL REFUSAL E-MAILED
- 18 Jul 2025 — FINAL REFUSAL WRITTEN
- 02 Jul 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 01 Jul 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 01 Jul 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED